Experimental drug targets root cause of rare genetic obesity
NCT ID NCT07220772
Summary
This study is testing an experimental drug called mibavademab for people with a rare genetic form of obesity caused by leptin gene mutations. The drug aims to help control body weight by targeting the underlying biological pathway that regulates hunger and fullness. Researchers will measure changes in BMI and body weight while monitoring safety in a small group of participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOGENIC OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ULM University Medical Centre
RECRUITINGUlm, 89075, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.